Literature DB >> 10087589

[Pseudomonas pneumonia--an important differential pulmonary infiltration diagnosis in AIDS].

P Kaufmann1, M Opravil, M Hauser, A Gaspert, I Laube, R Jenni, R Speich.   

Abstract

Bacterial pneumonias are the most common pulmonary complication in HIV-infected patients. Up to now, H. influenzae and S. pneumoniae have been described as the most important germs. Within a period of 4 years we diagnosed 15 cases of pneumonia caused by P. aeruginosa. All patients were in HIV stage C3; 3F, 12M; median age 34 (24-54) years; median CD4 count 10 (0-130) microliters. Except for 3 nosocomial pneumonias, all others were community-acquired. Only 3 patients had neutropenia < 1000/microliter; 7 were intravenous drug abusers. Morphologically there were 6 cases of abscess pneumonia, in 3 of which pleural drainage was necessary because of pyopneumothorax. 4 patients showed bilateral infiltrates that could not be differentiated from those of P. carinii pneumonia. Our diagnosis was based on quantitative cultures of broncho-alveolar lavage fluid (9 cases, two of them with concurrent positive blood cultures/positive cultures of the pleural fluid), pleural puncture (one case), sputum in pneumonias responding only to antipseudomonas therapy (3 cases), and autopsy (2 cases). 8 patients died of pseudomonas pneumonia within 1-3 months despite therapy. 7 patients received pseudomonas-specific combination therapy, but all died after median 9 (4-15) months of the underlying illness. In 3 cases recurrent pseudomonas pneumonia could be documented bacteriologically. We conclude that in HIV-infected patients pneumonia caused by P. aeruginosa is a significant and severe pulmonary complication.

Entities:  

Mesh:

Year:  1999        PMID: 10087589

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  1 in total

1.  Post-mortem histological pulmonary analysis in patients with HIV/AIDS.

Authors:  Alexandre de Matos Soeiro; André L D Hovnanian; Edwin Roger Parra; Mauro Canzian; Vera Luiza Capelozzi
Journal:  Clinics (Sao Paulo)       Date:  2008-08       Impact factor: 2.365

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.